{"filing":{"accession_number":"0001493152-26-044761","cik":"0001873835","ticker":"IMMX","company_name":"Immix Biopharma, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226044761/form8-k.htm"},"events":[{"id":35576,"run_id":32775,"accession_number":"0001493152-26-044761","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses positive interim clinical trial results from the Phase 2 NEXICART-2 trial of NXC-201, showing an 89% complete response rate across 45 relapsed/refractory AL Amyloidosis patients, with potential to reach 98% when accounting for MRD-negative patients. While the disclosure is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events) rather than a dedicated clinical-results Item, the substance is a material operational/clinical milestone for a biopharmaceutical company with a lead product candidate in Phase 2 development. This is not an earnings release (no financial results), but rather a clinical development milestone that would materially affect investor assessment of the company's pipeline progress and regulatory pathway toward BLA submission planned for mid-2027.","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":39669,"accession_number":"0001493152-26-044761","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive interim clinical trial results from the Phase 2 NEXICART-2 trial of NXC-201, showing an 89% complete response rate across 45 relapsed/refractory AL Amyloidosis patients, with potential to reach 98% when accounting for MRD-negative patients. While the disclosure is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events) rather than a dedicated clinical-results Item, the substance is a material operational/clinical milestone for a biopharmaceutical company with a lead product candidate in Phase 2 development. This is not an earnings release (no financial results), but rather a clinical development milestone that would materially affect investor assessment of the company's pipeline progress and regulatory pathway toward BLA submission planned for mid-2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:01:46.361789+00:00","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-09-29"}]}